

Please type a plus sign '+' inside this box →



PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/053,194
				Filing Date	January 16, 2002
				First Named Inventor	Guangping Gao et al
				Group Art Unit	1648 1676
Examiner Name	S. Foley M. Burkhart				
Sheet	1	of	3	Attorney Docket Number	GNVPN.037BUSA

TECH CENTER 1600/2900

APR 17 2002

RECEIVED

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
MB	AA	5,891,690	B1	B. Massie	04/06/1999
MB	AB	6,365,394	B1	G. Gao	04/02/2002

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup> (if known)			
MB	AL	WO	WO97/00326	A1	F. Fallaux	01/03/1997
MB	AM	WO	WO01/23597	A3	G. Gao	04/05/2001

Examiner Signature	<i>Mike Foley</i>	Date Considered	8-27-04
--------------------	-------------------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

APR 15 2002

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box → 

PATENT &amp; TRADEMARK OFFICE

RECEIVED

Substitute for Form 1449A/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)				Complete if Known	
				Application Number	10/053,194
				Filing Date	January 16, 2002
				First Named Inventor	Guangping Gao et al
				Group Art Unit	1648 1636
				Examiner Name	S. Foley M. Burkhardt
Sheet	2	of	3	Attorney Docket Number	GNVPN.037BUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS						
Examiners Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
NP	AR	Y. DAI et al, "Cellular and Humoral Immune Responses to Adenoviral Vectors Containing Factor IX Gene: Tolerization of Factor IX and Vector Antigens Allows for Long Term Expression", Proc. Natl. Acad. Sci. USA, 92:1401-1405 (February, 1995)				
MB	AS	F. FALLAUX et al, "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses", Hum. Gene Ther., 9:1909-1917 (September, 1998)				
MB	AT	G. GAO et al, "Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver Directed Gene Therapy", J. Virol., 70:8934-8943 (December, 1996)				
MB	AU	H. GILGENKRANTZ et al, "Transient Expression of Genes Transferred In Vivo into Heart Using First-Generation Adenoviral Vectors: Role of the Immune Response", Hum. Gene Ther., 6:1265-1274 (December, 1995)				
NP	AV	N. HABIB et al, "A Phase I/II Study of Hepatic Artery Infusion with stp53-CMV-Ad in Metastatic Malignant Liver Tumors", Hum. Gene Ther., 10:2019-2034 (October, 1999)				
MB	AW	K. HEHIR et al, "Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modification to Prevent their Occurrence", J. Virol., 70:8459-8467 (December, 1996)				
MB	AX	J. IMLER et al, "Trans-Complementation of E1-Deleted Adenovirus: A New Vector to Reduce the Possibility of Co-Dissemination of Wild Type and Recombinant Adenoviruses", Gene Ther., 3:75-84 (June, 1995)				
MB	AY	J. IMLER et al, "Novel Complementation Cell Lines Derived from Human Lung Carcinoma A549 Cells Support the Growth of E1-Deleted Adenovirus Vectors", Gene Ther., 3:75-84 (January, 1996)				

Examiner Signature	Millhobby	Date Considered	8-77-07
--------------------	-----------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

APR 15 2002

PTO/SB/08B (08-00)

<p>Substitute for Form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				<p>Complete if Known</p>	
				Application Number	10/053,194
				Filing Date	January 16, 2002
				First Named Inventor	Guangping Gao et al
				Group Art Unit	1648-1636
				Examiner Name	S. Ealey M. Burkhardt
Sheet	3	of	3	Attorney Docket Number	GNVPN.037BUSA

RECEIVED  
TECH CENTER 1600  
APR 17 2002  
1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
NB	AZ	H. LOCHMULLER et al, "Emergence of Early Region 1-Containing Replication-Competent Adenovirus in Stocks of Replication-Defective Adenovirus Recombinants (ΔE1 and ΔE3) During Multiple Passages in 293 Cells", Hum. Gene Ther., 5:1485-1491 (December, 1994)		
NB	AAR	J. WILSON et al, "Gene Therapy of Cystic Fibrosis Lung Disease Using E1 Deleted Adenoviruses: A Phase I Trial", Hum. Gene Ther., 5:501-519 (April, 1994)		
NB	AAS	Y. YANG et al, "Cellular Immunity to Viral Agents Limits E1-Deleted Adenoviruses for Gene Therapy", Proc. Natl. Acad. Sci. USA, 91:4407-4411 (May, 1994)		
NB	AAT	H. ZHOU et al, "Development of a Complementing Cell Line and a System for Construction of Adenovirus Vectors with E1 and E2a Deleted", J. Virol., 70:7030-7038 (October, 1996)		
NB	AAU	J. ZHU et al, "Characterization of Replication-Competent Adenovirus Isolates from Large Scale Production of a Recombinant Adenoviral Vector", Hum. Gene Ther., 10:113-121 (January, 1999)		
NB	AAV	G. GAO et al, "A Cell Line for High-Yield Production of E1-Deleted Adenovirus Vectors without the Emergence of Replication-Competent Virus", Hum. Gene Ther., 11:213-219 (January, 2000)		

Examiner Signature	Mile Blay	Date Considered	8-27-04
--------------------	-----------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.